FDA slaps Im­prim­is­Rx with a warn­ing let­ter over spon­sored ar­ti­cles in med­ical jour­nals

Im­prim­is­Rx is in hot wa­ter with the FDA for false and mis­lead­ing claims about its com­pound­ed drug for post­op­er­a­tive eye pain called Pred-Moxi-Brom.

Spon­sored ar­ti­cles that ran in two oph­thal­mol­o­gy jour­nals last year crossed the line by po­si­tion­ing the com­pound’s com­po­nents as FDA-ap­proved while Im­prim­is us­es bulk drug sub­stances, the FDA says in its let­ter. The ti­tle of one of the spon­sored ar­ti­cles is “Pred-Moxi-Brom: The Whole Is Greater Than The Sum Of Its Parts.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER